A major update was shared at the ISSCR 2026 Annual Meeting about the first clinical trial testing a new treatment for Huntington’s disease made from special human stem cells. This trial, called Regen4HD, is a big step forward in regenerative medicine—a field focused on repairing or replacing damaged cells and tissues in the body. Huntington’s disease is a slowly worsening brain disorder that affects movement, thinking, and mood. Currently, there are no treatments that can slow or stop the disease from getting worse, so scientists are exploring new approaches like this one to help.
The Regen4HD study is the first time this type of stem cell therapy is being tested in people with Huntington’s disease. It started after years of lab research, safety tests, and discussions with health regulators to ensure the treatment is safe and effective. The trial is enrolling adults aged 18 to 65 who have early symptoms of Huntington’s disease. The first part of the study (phase 1b) will focus on finding the safest dose by gradually increasing it. The second part (phase 2a) will then test that dose to see if it is well-tolerated.
Leslie Thompson, PhD, a researcher at the University of California, Irvine, explained the importance of this trial: “This clinical trial is the result of many years of hard work in the lab, safety studies, and discussions with the FDA. It’s a huge milestone for Huntington’s disease research. The families affected by this disease and their partnership with scientists have been a great source of motivation for us.”
Developing treatments for Huntington’s disease has been challenging. Scientists have had to figure out the best way to target the disease, how to deliver the therapy safely, and how to measure its effects over time. Recent advances in understanding the biology of Huntington’s disease have helped move this research closer to testing in people.
Right now, the main goal of this trial is to check if the treatment is safe. The researchers will also look for any early signs that the therapy might be helping, though it is still too early to know if it can slow the disease. Dr. Thompson added, “The first step is to make sure this treatment is safe. If future studies show that a single dose of this stem cell therapy can slow down the disease, it could make a real difference for people living with Huntington’s disease. But we won’t know that until we do more research.”